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Abstract In this study, we attempted to develop a mul-
timodality approach using chemotherapeutic agent mito-
mycin C, biologic agent tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL/Apo-2L), and mild
hyperthermia to treat colon cancer. For this study, human
colon cancer LS174T, LS180, HCT116 and CX-1 cells
were infected with secretory TRAIL-armed adenovirus
(Ad.TRAIL) and treated with chemotherapeutic agent
mitomycin C and hyperthermia. The combinatorial treat-
ment caused a synergistic induction of apoptosis which was
mediated through an increase in caspase activation. The
combinational treatment promoted the JNK-Bcl-xL-Bak
pathway which transmitted the synergistic effect through
the mitochondria-dependent apoptotic pathway. JNK sig-
naling led to Bcl-xL phosphorylation at serine 62, disso-
ciation of Bak from Bcl-xL, oligomerization of Bak,
alteration of mitochondrial membrane potential, and sub-
sequent cytochrome c release. Overexpression of
dominant-negative mutant of Bcl-xL (S62A), but not
dominant-positive mutant of Bcl-xL (S62D), suppressed
the synergistic death effect. Interestingly, Beclin-1 was
dissociated from Bcl-xL and overexpression of dominant-
negative mutant of Bcl-xL (S62A), but not dominant-
positive mutant of Bcl-xL (S62D), suppressed dissociation
of Beclin-1 from Bcl-xL. A combinatorial treatment of
mitomycin C, Ad.TRAIL and hyperthermia induced
Beclin-1 cleavage, but the Beclin-1 cleavage was abolished
in Beclin-1 double mutant (D133A/D146A) knock-in
HCT116 cells, suppressing the apoptosis induced by the
combination therapy. We believe that this study supports
the application of the multimodality approach to colon
cancer therapy.
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ATM Ataxia telangiectasia mutated
53BP1 p53-binding protein 1
BAX Bcl-2–associated X protein
Bcl-xL B-cell lymphoma-extra large
BRCA1 Early-onset familial breast and ovarian
cancer
c-FLIPL Long form of cellular FLICE-inhibitory
protein
Chk2 Checkpoint kinase 2
COX Cyclooxygenase
CRE8 Cre-expressing 293 cells
DMEM Dulbecco’s modified eagle medium
DR4 Death receptor 4
DR5 Death receptor 5
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FADD Fas-Associated protein with Death Domain
FBS Fetal bovine serum
FLICE FADD-like interleukin-1 beta-converting
enzyme
Flt3 fms-related tyrosine kinase 3
Flt3L Ligand for Flt3
HA Hemagglutinin
HIPEC Hyperthermic intraperitoneal chemotherapy
JNK c-Jun NH2-terminal kinase
KI Knock-in
MDC1 Mediator of DNA damage checkpoint 1
NBS1 Nijmegen breakage syndrome
PARP Poly (ADP-ribose) polymerase
PBS Phosphate-buffered saline solution
PI Propidium iodide
RPMI Roswell Park Memorial Institute medium
SDS Sodium dodecyl sulfate
PAGE Polyacrylamide gel electrophoresis
BH3 Bcl-2 homology domain 3
TNF Tumor necrosis factor




Colorectal cancer is the third leading cause of cancer-related
mortality in the world. The main cause of death of patients
with colorectal cancer is metastases [1]. In the last decade,
the medical control of metastatic colorectal cancer has
shown remarkable advances. For example, the addition of
oxaliplatin and irinotecan to previously existing 5-fluoro-
uracil (5-FU) and leucovorin-based therapies improved the
overall median survival of 12 months [2], and with the
addition of biological targeted therapies such as bev-
acizumab and cetuximab, the overall median survival rose to
20 months [3–8]. However, systemic chemotherapeutic
strategies are currently used only as palliatives—they do not
improve long-term survival rates. Therefore, new approa-
ches are necessary to improve the overall median survival
for metastatic colorectal cancers such as hepatic colorectal
metastases and colorectal peritoneal carcinomatosis.
Current standard of care for hepatic colorectal metas-
tases and colorectal peritoneal carcinomatosis is hyper-
thermic isolated hepatic perfusion (HIHP) therapy and
hyperthermic intraperitoneal chemotherapy (HIPEC),
respectively [9, 10]. These therapies are combinatorial
treatments of chemotherapeutic agents and mild hyper-
thermia. We hypothesize that a multimodality [chemo-
therapeutic agent mitomycin C, biologic agent tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL/
Apo-2L), and mild hyperthermia] approach effectively
enhances apoptotic death and improves the current stan-
dard of care to treat advanced colorectal metastases. To test
the hypothesis, in this study, we focus on the effect of
multimodality treatment on cell death in in vitro system.
Chemotherapy is the standard clinical treatment for
human cancers. Chemotherapeutics can interact with DNA
and activate several intracellular signal pathways including
apoptosis [11]. Mitomycin C is an antibiotic which has been
used as a chemotherapeutic agent in a variety of carcinogenic
solid tumors including colon [12], breast [13], lung [14] and
bladder [15]. Mitomycin C causes cross-links in the DNA
molecules of the cells, leading to the formation of DNA
interstrands and inhibiting DNA replication and transcrip-
tion [16, 17]. Previous reports suggest that mitomycin C
produces a consistent response when used as a single agent
[18–21]. However, like many other chemotherapeutic
agents, mitomycin C may induce resistance to chemotherapy
and may target normal cells, thus causing unexpected side
effects at therapeutic doses. On the other hand, since mito-
mycin C offers a suitably low toxicity and can be easily
delivered to an outpatient, it seems a reasonable, cost-
effective candidate for combinational therapy of colorectal
cancer, like irinotecan [22], capecitabine [23] or 5-FU [24].
TRAIL, a highly promising anticancer agent, is a cytokine
of the TNF family which binds to the death receptors DR4
[25–27] and DR5 [28–30]. It has the unique ability to induce
apoptosis in many transformed cancer cell lines, but not in
normal tissue [31, 32]. Previous studies suggest that TRAIL-
induced apoptosis can be enhanced by combinational therapy
with several chemotherapeutic agents at non-toxic doses in
cancer cells [33–38]. Nonetheless, the translation of TRAIL
into the clinic has been confounded by its short half-life,
inadequate delivery methods, and TRAIL-resistant cancer cell
populations [39]. To solve these limitations, we attempt to
develop a secretory TRAIL-armed adenoviral vector.
Hyperthermia has been explored as an anticancer agent
for many decades and is often used with HIPEC. We pre-
viously reported that hyperthermia has a synergistic effect
with TRAIL in causing cytotoxicity through the mito-
chondria-dependent pathway [40–43]. Several researchers
also reported that hyperthermia acts synergistically with
ionizing radiation [44–46], and with a number of chemo-
therapeutic agents [47–49]. We previously reported that
hyperthermia triggered down-regulation of c-FLIPL (long
form of cellular FLICE-inhibitory protein), an anti-apop-
totic molecule, in several colon cancer cells [50]. c-FLIP
splice variants (long and short form) bind to FADD and/or
caspase 8/10 and inhibit their activation [51–53].
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In this study, we observed that a combinatorial treatment
of mitomycin C, adenoviral TRAIL and hyperthermia
effectively activates the mitochondrial-dependent apoptotic
pathway by activating the JNK-Bcl-xL-Bak pathway,
increasing Bak oligomerization, facilitating cytochrome
c release, promoting dissociation of Beclin-1 from Bcl-xL,
and increasing Beclin-1 cleavage.
Materials and methods
Cell culture
The human colon adenocarcinoma line LS174T was kindly
provided by Dr. HA Choudry (University of Pittsburgh
Medical Center, Pittsburgh, PA, USA) and LS180 was pur-
chased from the American Type Culture Collection (ATCC,
Manassas, VA, USA). The human colorectal carcinoma
HCT116 wild type was obtained from Dr. B Vogelstein
(Johns Hopkins University) and CX-1 cell line was obtained
from Dr. JM Jessup (National Cancer Institute). Cell lines
were maintained in Dulbecco’s Modified Eagle Medium
(DMEM, Gibco, Gaithersburg, MD, USA), McCoy’s 5A or
RPMI 1640 supplemented with 10 % fetal bovine serum
(FBS, Atlanta Biological, Flowery Branch, GA, USA),
100 U/mL penicillin and 100 lg/mL streptomycin (Gibco)
in a 5 % CO2 incubator. These adherent cells, except for
LS180, were subcultured every 3–4 days by treatment with a
trypsin–EDTA solution (Gibco). The LS180 cell line was
cultured by following a procedure of ATCC subculturing.
Reagents and antibodies
Mitomycin C and anti-TRAIL antibody were obtained
from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-
PARP, anti-caspase 8/9/3, anti-cleaved caspase 9/3, anti-
phosphorylated (Thr183/Tyr185) JNK, anti-JNK, anti-Bcl-
xL, anti-COX-IV and anti-human influenza hemagglutinin
(HA) antibody were purchased from Cell Signaling (Dan-
vers, MA, USA). Anti-phosphorylated Bcl-xL (S62) anti-
body was purchased from Millipore (Billerica, MA, USA)
and anti-cytochrome c antibody and anti-Beclin-1 were
from BD Pharmigen (San Jose, CA, USA). Anti-actin
antibody and other chemicals were purchased from Sigma
(St. Louis, MO, USA).
Shuttle vector construction
pFETZ was kindly provided by Dr. Y He (Immunotherapy
Center, Medical College of Georgia, GA, USA) [54]. This
vector contains cDNA for the extracellular domain of
Flt3L, a ligand for Flt3 tyrosine kinase receptor (a.a. 1–81),
fused to a leucine zipper domain and the extracellular
domain of TRAIL (a.a. 95–281) and expresses a secretable
form of TRAIL fusion protein [55]. pAdlox-FETZ was
made by inserting the SalI/BamHI fragment from pFETZ
into SalI/BamHI-cut pAdlox shuttle vector. The complete
shuttle vector was co-transfected into CRE8 cells with w5
viral genomic DNA for homologous recombination as
described below.
Adenoviral vector construction
Recombinant adenovirus was constructed by employing the
Cre-lox recombination system [56]. The selective cell line
CRE8 has a b-actin-based expression cassette driving a Cre
recombinase gene with an N-terminal nuclear localization
signal stably integrated into 293 cells. Transfections were
done by using Lipofectamine reagent (Invitrogen, Carls-
bad, CA, USA). Cells were split into T25-flasks 1 day
before transfection. For the production of recombinant
adenovirus, 2 lg of Adlox/FETZ and 2 lg of w5 viral
genomic DNA were co-transfected into CRE8 cells in the
presence of caspase inhibitor z-VAD-fmk (20 lM). The
recombinant adenoviruses were generated by intramole-
cular homologous recombination between the shuttle vec-
tor and w5 viral DNA. The new virus had an intact
packaging site and carried a recombinant gene. Plaques
were harvested, analyzed and purified.
Drug treatment
Drug treatments were accomplished by aspirating the
medium and replacing it with new medium containing
drugs.
Hyperthermia treatment
Cells cultured in 35 mm or 100 mm dishes were sealed
with parafilm and were placed a circulating water bath
(Heto, Thomas Scientific, Denmark), which was main-
tained within 0.02 C of the desired temperature.
Survival assay
One or 2 days prior to the experiment, human colorectal
carcinoma LS174T cells were plated into six well plates.
For trypan blue exclusion assay, trypsinized cells were
pelleted and resuspended in 0.2 mL of medium, 0.5 mL of
0.4 % trypan blue solution, and 0.3 mL of phosphate-buf-
fered saline solution (PBS). The samples were mixed
thoroughly, incubated at room temperature for 15 min, and
examined by automated cell counter (LUNA, Logos Bio-
systems, Annandale, VA, USA). At least 300 cells were
counted for each survival determination.
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Protein extracts and polyacrylamide gel electrophoresis
(PAGE)
Cells were scraped with 1 9 Laemmli lysis buffer
[including 2.4 M glycerol, 0.14 M Tris (pH 6.8), 0.21 M
SDS, and 0.3 mM bromophenol blue] and boiled for 3 min.
Protein concentrations were measured with BCA protein
assay reagent (Pierce, Rockford, IL, USA). The samples
were diluted with 1 9 lysis buffer containing 20 mM
dithiothreitol (DTT), and an equal amount of protein was
loaded on 10–15 % SDS-polyacrylamide gels. SDS-PAGE
analysis was performed using a Hoefer gel apparatus.
Immunoblot analysis
Proteins were separated by SDS-PAGE, electrophoretically
transferred to nitrocellulose membranes and blocked with
5 % skim milk in TBS-Tween 20 (0.05 %, v/v) for 30 min.
The membrane was incubated with primary antibodies for
2 h at room temperature or overnight at 4 C. Horseradish
peroxidase-conjugated anti-rabbit or anti-mouse IgG was
used as the secondary antibody. Immunoreactive protein
was visualized by the enhanced chemi-luminescence pro-
tocol (ECL, Amersham, Arlington Heights, IL, USA).
Annexin V binding
The translocation of phosphatidylserine, one of the markers
of apoptosis, from the inner to the outer plasma membrane
was detected by binding of allophycocyanin (APC)-con-
jugated Annexin V. LS174T cells were plated into plates,
treated with drugs for 24 h and stained with mouse anti-
human Annexin V antibody and propidium iodide (PI). The
staining was terminated and cells were immediately ana-
lyzed by flow cytometry.
JC-1 mitochondrial membrane potential assay
After drug treatment, cells were stained using JC-1 mito-
chondrial membrane potential detection kit (Invitrogen) for
10 min and analyzed by flow cytometry. Fluorescence
intensity was measured with the Accuri C6 flow cytometer
(Accuri Cytometers, Inc., San Jose, CA, USA). Results
were analyzed with VenturiOne software (Applied
Cytometry, Inc., Plano, TX, USA).
Cytochrome c release assay
To determine the release of cytochrome c from the mito-
chondria, LS174T cells growing in 100 mm dishes were
used. After drug treatment, mitochondria and cytosolic
fractions were prepared from treated cells by using a
Mitochondrial Fractionation Kit (Active Motif, Carlsbad,
CA, USA) following company instructions and reagents
included in the kit. Cytosolic fractions were subjected to
SDS-PAGE and analyzed by immunoblotting using anti-
cytochrome c antibody. Equal loading of the mitochondrial
pellets was confirmed with anti-COX IV antibody.
Bak oligomerization
After drug treatment, cells were collected and resuspended
in homogenization buffer. The cell suspension was
homogenized several times and centrifuged at 1,0009g for
10 min at 4 C to obtain nuclear pellets. Supernatant was
transferred to a new 1.5 mL tube and spun at 10,0009g for
15 min at 4 C to pellet the mitochondria. Isolated mito-
chondrial fractions and cytosolic fractions were cross-
linked with 1 mmol/L dithiobis (Pierce) for 1 h at room
temperature. After cross-linking, the mitochondria were
pelleted and samples were subjected to SDS-PAGE under
nondenaturing conditions followed by immunoblotting for
Bak.
Stable transfection
Cells stably overexpressing HA-Bcl-xL wild-type (WT) or
mutant types were prepared by transfecting CX-1 cells with
human Bcl-xL tagged with HA epitope in pCDNA3.1
vector: HA-Bcl-xL WT, HA-Bcl-xL S62A (mutation of
serine 62 to alanine), and HA-Bcl-xL S62D (mutation of
serine 62 to aspartate; a kind gift from Dr. TC Chambers,
University of Arkansas). Cells were maintained in 500 lg/
mL G418.
Immunoprecipitation
Briefly, cells were pelleted and lysed by CHAPS buffer
with protease inhibitor cocktail. Cell lysates were com-
pletely disrupted by repeated aspiration through a 27 gauge
needle. Cell debris was removed and protein concentration
was determined by BCA Protein Assay Reagent. For
immunoprecipitation, 500 lg of lysate was incubated with
1 lg of rabbit anti-Bcl-xL/anti-HA antibody or rabbit IgG
at 4 C overnight, followed by the addition of protein
G-agarose beads and rotation at 4 C for 4 h. Immuno-
precipitates were collected by centrifugation and the pellet
was dissolved in electrophoresis sample buffer for heat
denaturation. The immune complexes were subjected to
SDS-PAGE followed by immunoblot analysis.
Statistical analysis
Statistical analysis was carried out using GraphPad InStat 3
software (GraphPad Software, Inc., San Diego, CA, USA).
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Significance was set at values of *(p \ 0.05), **(p \
0.01), or ***(p \ 0.001).
Results
Characterization of a secretory TRAIL-armed
adenoviral vector
We constructed pAdlox-FETZ shuttle vector which has a
CMV promoter-driven secretory human Flt3 ligand-iso-
leucine zipper-human TRAIL fusion protein gene. This
plasmid encoded the secretable form of chimeric TRAIL
proteins which were detected in Fig. 1a. Next, we con-
structed a secretory TRAIL-armed adenoviral vector
(Ad.TRAIL) and characterized the vector. Data from
Fig. 1b shows an expression of TRAIL in Ad.TRAIL
infected 293 cells in the absence/presence of caspase
inhibitor z-VAD-fmk, which was added to prevent TRAIL-
induced apoptosis. Unlike most cancer cell lines, immor-
talized normal human embryonic kidney 293 cells were
resistant to TRAIL. To examine an apoptotic capacity of
Ad.TRAIL, human colon adenocarcinoma LS174T cells
were infected with various multiplicity of infection (MOI)
of Ad.TRAIL and its control adenoviral construct encoding
green fluorescent protein (Ad.GFP). As shown in Fig. 1c,
Ad.TRAIL induced PARP cleavage, the hallmark feature
of apoptosis. TRAIL-induced PARP cleavage was depen-
dent upon MOI. Unlike Ad.TRAIL, Ad.GFP induced
minimal apoptosis only at MOI of 100. Next, we investi-
gated the kinetics of apoptosis after Ad.TRAIL infection in
human colorectal carcinoma HCT116 and LS174T cells.
Figure 1d shows that PARP cleavage occurred 24 h after
infection in both cell lines.
Synergistic induction of apoptosis by Ad.TRAIL
in combination with mitomycin C and hyperthermia
To investigate the effect on cell viability of the application
of Ad.TRAIL in combination with mitomycin C and
hyperthermia, LS174T cells were infected with Ad.TRAIL
(MOI 25) and treated with 5 lg/mL mitomycin C for 24 h.
After treatment, the cells were heated at 42 C for 1 h and
incubated at 37 C for 3 h and then cell viability was
determined by trypan blue dye exclusion assay. As shown
in Fig. 2a, synergistic cytotoxic effect was observed in
Ad.TRAIL ? mitomycin C or Ad.TRAIL ? mitomycin
C ? hyperthermia compared with any single treatment
(p \ 0.05). We further investigated whether the combina-
torial treatment-induced cytotoxicity was associated with
Fig. 1 Production of secretory TRAIL and its cytotoxicity. a 293
cells were non-transfected (lane 1), or transfected with 4 lg pAdlox
empty vector (lane 2) or pAdlox-FETZ vector (lane 3, 4) and then
incubated for 48 h. After incubation, 30 lg of cell lysate protein (lane
1, 2, 3, and 4) or 30 lL of cell culture medium (lane 5, 6) were
immunoblotted with anti-TRAIL antibody. b 293 cells were infected
with Ad.TRAIL (MOI 10) in the presence/absence of caspase
inhibitor (20 lM). Cell lysates were prepared in lysis buffer and
immunoblotted with anti-TRAIL. c LS174T cells were infected by
various MOI of Ad.TRAIL or Ad.GFP for 24 h and harvested. Cell
lysates were immunoblotted with anti-PARP antibody. d HCT116 and
LS174T cells were infected with Ad.TRAIL (MOI 50) and harvested
at various time points. Cell lysates were immunoblotted with anti-
PARP antibody. Actin was used as an internal standard
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apoptosis. Data from the flow cytometry assay demonstrate
that the combinatorial treatment-induced cytotoxicity was
associated with apoptosis (Figs. 2b, c); apoptotic death
cells were observed in the lower right quadrant (early
apoptotic death) and the upper right quadrant (late apop-
totic death) of the plots. The results from Figs. 2b, c clearly
demonstrate that apoptosis was time-dependent during
combined treatment. Figures 2b, c clearly show that treat-
ment with Ad.TRAIL in combination with mitomycin C
and hyperthermia enhanced synergistic induction of apop-
totic death. These synergistic effects were due to an
increased activation (cleavage) of caspase 8/9/3 and thus,
the hallmark feature of apoptosis, PARP cleavage
(Fig. 3a). Similar results were observed in LS180, CX-1
and HCT116 cell lines (Figs. 3b, c, d). These results
indicate that synergistic induction of apoptosis by combi-
natorial treatment with mitomycin C/Ad.TRAIL/hyper-
thermia is mediated through an increase in caspase
activation.
Role of the JNK-Bcl-xL-Bak pathway
in the combinatorial treatment-induced apoptosis
We previously reported that the JNK-Bcl-xL pathway plays
an important role in the synergistic effect on apoptosis of
treatment with multiple cytotoxic agents [43, 57]. This
possibility was examined during treatment with mitomycin
C/Ad.TRAIL/hyperthermia. Phosphorylation of JNK and
Bcl-xL was observed during treatment with mitomycin
C/Ad.TRAIL/hyperthermia in LS174T cells (Fig. 4a).
Even with treatment with only mitomycin C, phosphory-
lation of JNK and Bcl-xL was detected. Moreover, an
increase in phosphorylation was observed during combi-
natorial therapy. Data from immunoprecipitation assay
show that the combinatorial treatment induced the disso-
ciation of Bak from Bcl-xL (Fig. 4b). We previously
reported that phosphorylation of Bcl-xL alters the interac-
tions between Bcl-xL and Bax and then leads to Bax
oligomerization [43]. Since the presence of Bax was not
Fig. 2 Synergistic induction of cytotoxicity by treatment with
Ad.TRAIL in combination with mitomycin C and hyperthermia in
LS174T cells. LS174T cells were treated with Ad.TRAIL (MOI 25)
or/and mitomycin C (5 lg/mL) for 24 h and exposed to normothermia
(37 C) or hyperthermia (42 C) for 1 h, and then incubated for 3 h at
37 C. a Cell survival was analyzed by the trypan blue dye exclusion
assay. b Cells were stained with fluorescein isothiocyanate (FITC)-
Annexin V and propidium iodide (PI). c Cells were treated with
Ad.TRAIL (MOI 25) and mitomycin C (5 lg/mL) for 4, 8, and 16 h
and exposed to hyperthermia (42 C) for 1 h, and then incubated for
3 h at 37 C. Apoptosis was detected by the flow-cytometric assay
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detected in LS174T cells (data not shown), we examined
Bak oligomerization. Bak oligomerization occurred during
treatment with Ad.TRAIL in combination with mitomycin
C with/without hyperthermia (Fig. 4c). Oligomerized Bak
may bind to the mitochondria, altering mitochondrial
membrane potential (Fig. 4d) and causing a cytochrome c
release (Fig. 4e).
Alteration of interactions between Bcl-xL and Beclin-1
and cleavage of Beclin-1 during the combinatorial
treatment
To examine whether phosphorylation of the S62 residue on
Bcl-xL is important for apoptosis, CX-1 cells were stably
transfected with plasmid containing HA-Bcl-xL WT,
phosphor-defective HA-Bcl-xL S62A or phosphor-mimic
HA-Bcl-xL S62D. Figure 5a shows that HA-Bcl-xL S62A,
but not HA-Bcl-xL WT and HA-Bcl-xL S62D, inhibited
apoptosis. These results suggest that the phosphorylation of
Bcl-xL plays an important role in the combinatorial treat-
ment-induced apoptosis. We previously reported that
phosphorylation of Bcl-xL affects interaction between Bcl-
xL and Beclin-1, causing dissociation of Beclin-1 from
Bcl-xL [57]. Data from immunoprecipitation assay show
that overexpression of dominant-negative mutant type of
Bcl-xL S62A, but not wild type Bcl-xL WT or dominant-
positive mutant type of Bcl-xL S62D, suppressed the dis-
sociation of Beclin-1 from Bcl-xL (Fig. 5b). Several
researchers reported that Beclin-1 has two cleavage sites at
D133 and D146 residues [58] and that Beclin-1 is cleaved
by caspase 8, and C-terminal fragment of Beclin-1 local-
izes at the mitochondria and then induces cytochrome
c release [58, 59]. Figure 6a shows that the combinatorial
treatment enhanced Beclin-1 cleavage. On Fig. 6b, data
from Beclin-1 double mutant (D133A/D146A) knock-in
HCT116 cells show suppression of cleavage of PARP and
caspase 8/9/3 (apoptosis). Beclin-1, a mammalian homolog
of yeast autophagy-related protein 6 (Atg6), functions in
autophagy by initiating autophagosome formation [60].
However, it has been suggested that crosstalk between
apoptosis and autophagy is associated with caspase-medi-
ated cleavage of Beclin-1 which destroys its pro-autopha-
gic activity and can then amplify mitrochondrion-mediated
apoptosis through the cleaved C-terminal fragment [58].
Fig. 3 Synergistic induction of apoptosis by treatment with
Ad.TRAIL in combination with mitomycin C and hyperthermia in
colon cancer cells. LS174T (a), LS180 (b), CX-1 (c) and HCT116
(d) cells were treated with Ad.TRAIL (MOI 25 or 50) or/and
mitomycin C (3.5 or 5 lg/mL) for 24 h and exposed to normothermia
(37 C) or hyperthermia (42 C) for 1 h, and then incubated for 3 h at
37 C. After treatment, the cleavage of caspase 8/9/3 or PARP was
detected by immunoblotting. Actin was used to confirm the equal
amount of proteins loaded in each lane
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Our data suggest that the combinatorial treatment-induced
synergistic apoptotic death is mediated through Beclin-1
cleavage.
Discussion
Several conclusions can be drawn upon consideration of
the data presented here. First, a combinatorial treatment of
Ad.TRAIL, mitomycin C and hyperthermia synergistically
induces apoptosis. Second, the JNK-Bcl-xL-Bak pathway
plays an important role in the apoptosis through activating
the mitochondria-dependent pathway. Third, a combinato-
rial treatment of Ad.TRAIL, mitomycin C and hyperther-
mia induces dissociation of Beclin-1 from Bcl-xL and
promotes Beclin-1 cleavage which results in enhancement
of apoptosis.
The DNA damage surveillance network may orchestrate
cellular responses to mitomycin C-induced DNA damage
through the recruitment of DNA damage sensing mole-
cules, transducer and effector proteins [61]. Ataxia telan-
giectasia mutated (ATM) and Nijmegen breakage
syndrome (NBS1) cooperatively sense DNA damage and
post-translationally modify transducers such as BRCA1
(early-onset familial breast and ovarian cancer), MDC1
(mediator of DNA damage checkpoint 1), 53BP1 (p53-
binding protein 1), and c-Abl [62, 63]. These modified
transducer proteins amplify and transduce the signals to
downstream effectors such as H2AX, p53, Chk2 and JNK
[64–72]. It is possible that mitomycin C-activated JNK is
mediated through the ATM-c-Abl signal transduction
pathway. This possibility needs to be further investigated.
We previously reported that Bcl-xL undergoes phos-
phorylation in response to treatment with oxaliplatin,
TRAIL/mapatumumab and hyperthermia [42, 43, 57, 73–
75]. Bcl-xL phosphorylation requires activated JNK, which
can recognize a proline residue on the carboxyl side of the
phospho-acceptor [76]. Some studies reported Bcl-xL
phosphorylation to occur on serine 62, while others
reported it to occur on threonines 47 and 115 [77, 78]. This
study with site-directed mutagenesis at Ser-62 showed that
cells expressing a validated phospho-defective Bcl-xL
mutant are resistant to the combinatorial treatment of
Ad.TRAIL, mitomycin C and hyperthermia-induced
apoptosis, whereas cells expressing a phospho-mimic Bcl-
xL are sensitive to the combinatorial treatment-induced
apoptosis, indicating that phosphorylation at Ser-62 is a
key regulatory mechanism for antagonizing anti-apoptotic
function in the combinatorial treatment.
Previous studies have shown that JNK1-mediated
phosphorylation of Bcl-2 at residues T69, S70, and S87 is
bFig. 4 Ad.TRAIL in combination with mitomycin C and hyperther-
mia-induced activation of the JNK-Bcl-xL pathway, Bak oligomer-
ization, mitochondrial membrane potential change and cytochrome
c release. LS174T cells were treated with Ad.TRAIL (MOI 25) or/and
mitomycin C (5 lg/mL) for 24 h and exposed to normothermia
(37 C) or hyperthermia (42 C) for 1 h, and then incubated for 3 h at
37 C. a After treatment, cell lysates containing equal amounts of
protein were separated by SDS-PAGE and immunoblotted with anti-
phospho-JNK, anti-JNK, anti-phospho Bcl-xL or anti-Bcl-xL anti-
body. b Cell lysates were immunoprecipitated with anti-Bcl-xL
antibody or IgG and immunoblotted with anti-Bak antibody. The
presence of Bcl-xL and Bak in the lysates was examined. Asterisk (*)
is IgG light chain (LC). c Mitochondrial and cytosolic fractions were
isolated and were cross-linked with 1 M DSP (dithiobis, succinimidyl
propionate) for 30 min and then subjected to immunoblotting with
anti-Bak antibody. Bak monomer (91) and multimer (92, 93) are
indicated. COX IV and actin were shown as an internal standard of
mitochondrial fraction and cytosolic fraction, respectively. d Cells
were stained with JC-1 and then analyzed by flow cytometry.
e Cytochrome c release into cytosol was determined by immunoblot-
ting for cytochrome c in the cytosolic fraction. Actin was used to
confirm the equal amount of proteins loaded
Fig. 5 Role of Bcl-xL in apoptosis. CX-1 cells were stably transfec-
ted with HA-Bcl-xL WT, HA-Bcl-xL S62A or HA-Bcl-xL S62D
plasmid and then treated with Ad.TRAIL (MOI 25) and/or mitomycin
C (5 lg/mL) for 24 h and exposed to normothermia (37 C) or
hyperthermia (42 C) for 1 h, and then incubated for 3 h at 37 C.
a After treatment, lysates containing equal amounts of protein were
separated by SDS-PAGE and PARP cleavage was detected by
immunoblotting. Actin was used as an internal standard. b Cell
lysates were immunoprecipitated with anti-HA antibody or mock
antibody (IgG) and immunoblotted with anti-Beclin-1 or anti-HA
antibody (upper panels). The presence of Beclin-1 and actin in the
lysates was examined (lower panels)
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required for dissociation of Bcl-2 from Beclin-1 and
autophagy activation [79]. Unlike Bcl-2, data from Fig. 5b
suggests that for Bcl-xL, phosphorylation only at residue
S62 may be sufficient for Bcl-xL dissociation from Beclin-
1. It was reported that D133 and D146 of Beclin-1 are
cleaved by caspase 8 during apoptosis [58, 59]. Caspase
8-mediated cleavage of Beclin-1 inactivates Beclin-1-
induced autophagy and enhances apoptosis by promoting
the release of proapoptotic factors from mitochondria [58,
59]. Studies with the caspase 8-resistant Beclin-1 knockin
cell line clearly demonstrate that the combinatorial treat-
ment-induced Beclin-1 cleavage and apoptosis were
reduced (Fig. 6b), and Beclin-1’s autophagy-promoting
function was restored (data not shown) in Beclin-1 KI
HCT116 cells.
We reported that hyperthermia has a synergistic effect
with TRAIL in causing apoptosis [40–42]. We also
reported that hyperthermia triggers down-regulation of
c-FLIPL (long form of cellular FLICE-inhibitory protein),
an anti-apoptotic molecule, through ubquitination in
several colon cancer cell lines [50]. It has been found that
c-FLIP splice variants (long and short form) bind to FADD
and/or caspase 8/10 and inhibit their activation [51–53].
Thus, down-regulation of c-FLIPL is probably responsible
for hyperthermia-enhanced TRAIL cytotoxicity. Interest-
ingly, long-term pretreatment with TRAIL by expressing
TRAIL from Ad.TRAIL showed a minimal synergistic
effect with hyperthermia, even though down-regulation of
c-FLIPL was observed (data not shown). This may be due
to the activation of TRAIL-associated death signals prior to
hyperthermia. This possibility needs to be further studied.
Our data illustrate that a combinatorial treatment of
Ad.TRAIL, mitomycin C and mild hyperthermia syner-
gistically induces apoptosis and effectively activates the
mitochondria-dependent apoptotic pathway by activating
the JNK-Bcl-xL-Bak pathway. Moreover, our data suggest
that Beclin-1 is dissociated from phosphorylated Bcl-xL
and cleaved during treatment with Ad.TRAIL, mitomycin
C and hyperthermia. The cleavage of Beclin-1 promoted
the combinatorial treatment-induced apoptotic death. The
studies presented here further elucidate a crosstalk between
the JNK-Bcl-xL-Bak pathway and the Bcl-xL/Beclin-1-
mediated pathway during treatment with Ad.TRAIL,
mitomycin C and hyperthermia. A greater understanding of
these interactions may be critical for enhancing the com-
binatorial treatment.
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